Shots:
- Welcome to the August edition of Know Your Investor, featuring leading venture capital firms fuelling innovation in healthcare and life sciences
- This edition spotlights Venrock Healthcare Capital Partners, a venture capital fund focused on investments in both publicly and privately held healthcare companies
- In 2024, Venrock Healthcare Capital Partners invested approximately $4.56B across six funding rounds, adding 32 healthcare and biotech companies to its growing portfolio. For the full report, contact us at connect@pharmashots.com.
Venrock Healthcare Capital Partners is a healthcare-focused venture capital fund managed by Venrock, the venture arm of the Rockefeller family. Founded in 1969 and headquartered in Palo Alto, California, Venrock invests across early-stage, late-stage, and post-IPO companies in the healthcare space. Its diverse portfolio includes notable companies such as Check Point Software, CloudFlare, Dollar Shave Club, Gilead Sciences, and Idec Pharma.
In 2024, Venrock participated in six funding rounds across various stages including Seed, PIPE, and Series A–D. Key additions to its portfolio include:
- Cidara Therapeutics
- enGene Holdings
- Bright Peak Therapeutics
- Averto Medical
The firm’s largest single investment was a $400M Series A funding in Mirador Therapeutics.
Venrock Healthcare Capital Partners focuses on the technology and healthcare sectors, with a strong emphasis on biotechnology, specialty pharmaceuticals, medical devices, diagnostics, and life science tools and services. The firm targets companies developing or commercializing innovative products and technologies in these areas, aiming to leverage the diverse opportunities and potential high‑value outcomes in biotech and healthcare innovation. Its investment strategy spans both publicly traded and privately held companies.
Therapeutic Areas of Focus:
- Oncology
- Infectious diseases
- Ophthalmic
- Immunology
- Ophthalmology
- Hepatology
- Dermatology
- Cardiology
Technological Focus:
- Antibodies
- Small molecules
- Biologics
- Cell and gene therapies
- Immunotherapies
- Peptides
- Antibody conjugates
- AI/ML
- Digihealth
In 2024:
- Total Companies Invested In: 32
- PIPE Funding: 56.2% of investments
- Series A & B: 25% of investments
Key Investments in 2024:
- $400M Series A - Mirador Therapeutics
- $325M PIPE - Ocular Therapeutix
- $280M PIPE - Cullinan Therapeutics
Quarterly Investments in 2024:
- Q1: 14 investments worth $2.24B
- Q2: 7 investments worth $782.1M
- Q3: 5 investments worth $858M
- Q4: 6 investments worth $680.1M
The table below depicts the top 5 out of the 32 investments made by Venrock Healthcare Capital Partners:
Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line “Venrock Healthcare Capital Partners Investment” or for early access to complete data for future reports and analysis, register here: https://forms.office.com/r/VwFu6aUm80)